Mini review: The clinical avenues of combined hydralazine-nitrate in subjects with heart failure with reduced ejection fraction.
Background: Combined hydralazine-nitrate has an avenue in the management of subjects with heart failure with reduced ejection fraction. Exploring the pharmacotherapy in this context will facilitate the clinical utility of the combined therapy. Objective: The main objective of this mini-review was to...
| Publicado en: | Pharmacy Practice (1886-3655) Vol. 21; no. 2; pp. 1 - 8 |
|---|---|
| Autores principales: | , , , , , , , , , , , , , , |
| Formato: | research systematic review tables/charts Journal Article |
| Publicado: |
Centro de Investigaciones y Publicaciones Farmaceuticas S.L.
Apr-Jun2023
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=169732675&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 169732675 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 1885642X 3EAU jtl: Pharmacy Practice (1886-3655) issn: 1885642X maglogo: N pubinfo: dt: Apr-Jun2023 vid: 21 iid: 2 pid: 36266 pub: Centro de Investigaciones y Publicaciones Farmaceuticas S.L. artinfo: ui: 169732675 169732675 169732675 10.18549/PharmPract.2023.2.2824 169732675 ppf: 1 ppct: 7 formats: fmt: @attributes: type: P tig: atl: Mini review: The clinical avenues of combined hydralazine-nitrate in subjects with heart failure with reduced ejection fraction. aug: au: Elnour, Asim Ahmed Sadeq, Adel Ramadan, Azza AlAmoodi, Abdulla Alkwarit, Alin Alshammari, Asma Faisal EL Khidir, Israa Yousif Alrashidi, Nouf Eid kouhgard, Parisa Qahtani, Mariam Mohamed Al Beshir, Semira Abdi Al-Kubaisi, Khalid Awad Al Mazrouei, Nadia Alkaabi, Maisoun Ashoor, Afaf affil: PhD, MSc. Clinical Pharmacy Program, College of Pharmacy, Al Ain University, Abu Dhabi campus, Abu Dhabi-United Arab Emirates sug: subj: Hydralazine Therapeutic Use Nitrates Therapeutic Use Drug Combinations Therapeutic Use Heart Failure Drug Therapy Ventricular Ejection Fraction Human Systematic Review Medline PubMed Hydralazine Administration and Dosage Nitrates Administration and Dosage Diuretics Therapeutic Use ab: Background: Combined hydralazine-nitrate has an avenue in the management of subjects with heart failure with reduced ejection fraction. Exploring the pharmacotherapy in this context will facilitate the clinical utility of the combined therapy. Objective: The main objective of this mini-review was to evaluate the role of combined hydralazine-nitrate in subjects with heart failure with reduced ejection fraction. Methods: We conducted a literature search on Google scholar, MEDLINE, and PubMed to identify the randomized clinical trials on combined hydralazine-nitrate, in subjects with heart failure with reduced ejection fraction. 2760 articles were returned initially out of which 10 trials were conforming to the inclusion criteria. However, three trails were the focus for the current mini-review. Key findings: The current mini-review lends support to the use of combined hydralazine-nitrate in subjects with heart failure with reduced ejection fraction (HFrEF). The combination may offer subjects who have remained symptomatic with HFrEF despite optimum dosing of standard therapy. Black subjects with HFrEF have proved to benefit from combined hydralazine-nitrate. The combination (e.g. small dose of hydralazine 12.5-25 mg twice a day and isosorbide mononitrate 10 mg twice a day) may provide alternative clinical utility in subjects with contraindications (renal artery stenosis, creatinine clearance less than 30 mL/minute, sustained hyperkalemia) to the use of ACEinh, ARBs, and/or ARNI. Subjects with HFrEF on combined hydralazine-nitrate should be assessed and monitored for systolic BP (keep >120 mmHg) and subjects with chronic kidney disease (keep eGFR > 30 mL/min/1.73 m2). Hydralazine-nitrate was inferior to ACEinh (higher all-cause mortality and cardiovascular mortality. Conclusion: The current minireview provides the key points to support the use of hydralazine-nitrate in subjects with heart failure with reduced ejection fraction. pubtype: Academic Journal doctype: research systematic review tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|